


Epigenomics AG
Oppenheimer 22nd Annual Healthcare Conference
New York, 13rd December 2011

Geert W. Nygaard | CEO



Safe Harbor

- **Forward Looking Statements**

This communication contains certain forward-looking statements, including, without limitation, statements containing the words “expects”, “future”, “potential” and words of similar import. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

- **Legal Product Disclaimer**

Products by Epigenomics that are referred to in this presentation are not available for sale in the United States. The analytical and performance characteristics of any product to be eventually sold in the U.S. based on our technology have not been established.

————— finding cancer early
epigenomics




Leader in *molecular diagnostics* with *proprietary*
products for the early detection of *cancer*

World's first marketed *blood-based test for early
detection of colorectal cancer* –
globally available as IVD or LDT test



Colorectal Cancer (CRC) Screening Saves Lives....

- CRC is the second largest cancer killer - 135.000 new cases and 55.000 deaths each year in the US
- Disease of the developed world: Highest prevalence in North America and Europe (15-20 deaths per 100.000 inhabitants¹)
- CRC is curable if detected early enough!
- 5-year survival for diagnosed and treated Stage I/II CRC: 90%
- CRC screening has proven to reduce mortality



	5-year survival ²
with screening	73%
without screening	46%

1) http://en.wikipedia.org/wiki/Colorectal_cancer 2) Survival rate for colorectal cancer by stage. Source: National Cancer Institute, PDQ, Treatment, Health Professionals www.meds.com/pdq/colon_pro.html

CRC Screening Saves Money

US\$ 14+ billion

total colorectal cancer related annual costs incurred in the U.S.



Key Challenge: non-compliance to existing stool-based or invasive (colonoscopy) CRC screening options




Centers for Disease Control. "Vital signs: Colorectal cancer screening, incidence, and mortality---United States, 2002-2010." MMWR Morb. Mortal. Weekly Report. 2011, 60(26):884-889.

Blood-based Septin9 Tests: Screening the Unscreened


Current CRC Screening Compliance in the US



A simple blood test for early detection of colorectal cancer:




The Septin9 test



American Cancer Society. Colorectal Facts and Figures 2011-2013. American Cancer Society 2011.


Blood-based Septin9 Tests: Benefits for Doctors and Patients



- non-invasive
- no dietary/medication restrictions
- quick and easy, done anytime
- helps with screening resistant patients

**Septin9-Test:
a simple blood draw is enough**

Clinical Application of Septin9 Tests in CRC Screening




Repeat blood test conducted at intervals consistent with practice guidelines and other non-invasive CRC screening tests, e.g. annually.

**Colonoscopy according to guidelines Next CRC screening colonoscopy to be performed according to guidelines, e.g. 10 years later
Appropriate repeat blood test interval frequency according to practice guidelines**

Septin9 Test for CRC Screening

- Proprietary Biomarker: ***methylated Septin9 gene***
- Detection of cell-free tumor DNA in blood by established ***real time PCR*** test
- High analytical sensitivity: up to ***6 pg / ml*** methylated Septin9
- Strong ***patent position***: Biomarkers, technology, processes
- 13 published retrospective clinical studies performed, ***>4,300 subjects tested***
- ***Prospective clinical screening study*** recently completed



Epi proColon[®]: 2nd Generation Product for the U.S. and EU Markets

**One assay –
one marker
-> Simple
qualitative
interpretation**



- Easy & fast: real-time PCR based, **8 hours time to result**
- FDA-compliant: **cGMP** manufactured; runs on **FDA cleared** real-time PCR **device**
- Automated: manual and different **automation options** possible
- Flexible: adapted to market requirements: high **sensitivity** and high **specificity!**

Epi proColon[®]: Clinical Validation Studies recently published

	Prospective Screening Study as a pivotal clinical trial for FDA	PRESEPT Study (first prospective screening study)	Case Control Study (high sensitivity configuration)	Case Control Study by ARUP
Samples	7,940*	7,940*	247	144
Sensitivity	68% ¹	66.7% ²	95% ³	90% ⁴
Specificity	80% ¹	88.4% ²	85% ³	88% ⁴
Assay	Epi proColon [®] 2.0 US	Epi proColon [®] CE (triplicate)	Epi proColon [®] 2.0 CE	LDT test developed and optimized at ARUP


*tested samples selected from a prospectively collected cohort of 7,940 individuals at average risk for CRC. Tested samples included all CRC cases, all adenomas and significant number of polyps identified in this cohort in addition to a randomized selection of study individuals with no evidence of disease (NED)

1) Prospective screening study results with Epi proColon[®] 2.0 final product published Dec 9, 2011 2) Results according to Epigenomics' announcement dated May 5, 2010; final and detailed results were published at DDW, New Orleans on 4 May 2010 by the Clinical Study Steering Committee. 3) Case control study results with Epi proColon[®] 2.0 final product published Sep 19, 2011 4) Case control study results with ARUP's LDT test published Nov 16, 2011

Clinical Validation Study Results: Next Steps

- Study results at lower end of company's expectations
- Analyzing data in detail to find additional information to explain findings
- Recent meeting held with FDA
- Modular PMA submission process to be initiated imminently
- Additional head-to-head comparison to FIT will be initiated and will become integral part of PMA submission
- Update on clinical and regulatory timeline to be provided in due course

2012 and Beyond



ColoVantage™ - Example of Fast Adoption in the United States

- Laboratory-developed Septin9 test by Quest Diagnostics
- Offered as LDT by Quest under license from Epigenomics
- Approved by New York State Department of Health
- Available coast-to-coast
- Actively promoted since early 2011
- Strong growth since launch 21,000 tests until the end of Oct
- Licensed until first FDA-approved Septin9 IVD test becomes available



services

Lab & Healthcare Services

Find a Quest Diagnostics Location
Make an Appointment
Confirm / Change / Cancel Appt
Get My Results
Diagnostic Services
Health Plan Services
Patient Health Library
Health Reminder Emails
Employer Solutions
Health & Wellness Programs
International Locations
Hospital Services
Test Menu

Featured Lab Tests

All Featured Lab Tests
AccuType® CP
Cardio CRP®
ColoVantage™ (methylated Septin 9)
ImmunoCAP® Specific IgE Blood Test
Leumeta™ Cancer Tests
OVA1™
Pain Management
QuantIFERON®-TB Gold
Transplant Testing
XSense® Fragile X with Reflex

Welcome to Quest Diagnostics

The world's leader in diagnostic testing, information, and services

[En Español](#)



patients & consumers

healthcare professionals

employer solutions

about our company

[contact us](#)

Careers
Press Releases
Newsroom
Investor Relations
Privacy Policy
Site Directory
Terms & Conditions

[Make appointment](#)

[Confirm / change / cancel appt](#)

[Find location](#)

[Get my results](#)

in the spotlight

ColoVantage™ – A Convenient Blood Test for Colorectal Cancer

Aids in the detection of colorectal cancer in patients who are non-adherent to current testing modalities*

[Learn More >](#)

*Not a replacement for colonoscopy

Septin9: One Biomarker – Several Tests – Global Availability

Septin9

Biomarker and Assay Technology Proprietary to Epigenomics

IVD Test Kits* / co-exclusive “group of 4”

**Epigenomics &
Distributors**

Abbott Molecular

QIAGEN

Sysmex

**Epi proColon®
EU/Middle East**

**mS9™
EU/Asia/Pacific**

*Option for the global
product license
In development
for use on QIAGEN platform*

*Option for the Japanese
Market*

* mid to high teen royalties from IVD kit sales by partners

Epi proLung[®] - Market Introduction

- Marketed in Europe since mid-2010
- Confirmatory test for the precise diagnostic of lung cancer
- Biomarker: ***m*SHOX2**
- Excellent validation data:
 - 81% sensitivity**
 - 95% specificity**
- Currently several ongoing studies in Europe
- Distributors in various markets signed-up



Key Financials 9M 2011

- Tightly controlled spending – funded well into 2013
- Number of employees (projected by end Q1 / 2012): 45
- Controlled build-up of US commercial operation underway


(in € thousand)	9M 2011	9M 2010
Revenue	1,242	1,336
EBIT (Operating Results)	-10,748	-8,443

(in € thousand)	09/30/2011	12/31/2010
Liquid Assets*	17,386	26,369
Number of Employees	77	82

* incl. marketable securities

Full financial statements: <http://www.epigenomics.com/en/news-investors/investors/financial-reports.html>

Current Shareholder Structure



- Listed on Frankfurt Stock Exchange - 8,818,417 shares outstanding

As of Jan 31, 2011 and according to voting rights notifications by the shareholders

Why Invest in Epigenomics....



- The world's first IVD blood test for early detection of colorectal cancer:
 - prospectively validated**
 - proven utility in CRC early detection**
 - globally available as IVD or LDT**
 - in development as IVD for the US market**
- IVD test for lung cancer diagnosis in the EU market
- Partnerships with leading international diagnostics companies

The leader in colorectal cancer screening!

Financial Calendar 2011 / 2012

- **Report on Business 2010**
Annual press conference and
Analyst meeting
Frankfurt am Main
Friday, March 23, 2012
- **Annual Shareholders' Meeting 2012**
Berlin
Wednesday, May 02, 2012*
- **3-Month Report 2012**
January 1 - March 31, 2012
Wednesday, May 09, 2012*
- **6-Month Report 2012**
January 1 – June 30, 2012
Wednesday, August 08, 2012*
- **9-Month Report 2012**
January 1 - September 30, 2012
Wednesday, November 7, 2012*

*tentative dates

Thank you for your attention!

Contact Investor Relations

Europe

Antje Zeise
Manager Investor Relations
Epigenomics AG
T +49 30 24345 0
ir@epigenomics.com

USA

Christine Yang
Vice President
The Trout Group LLC
T +1 646 378 2929
cyang@troutgroup.com

TICKER

Bloomberg: ECX:GR

Reuters: EXXG.DE

Thomson ONE: ECX-XE

INTERNET

www.epigenomics.com

www.epiprocolon.com

www.epiprolung.com